CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Earlier this month, Moderna CEO Stephane Bancel admitted that operations have been severely impacted by the drying up of demand for vaccines in a post-pandemic world and that Moderna only had two ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

It expects to end 2025 with a cash balance of $6 billion. Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and ...

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...